<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DA82066A-2B1B-412F-8D72-43273A319CA6"><gtr:id>DA82066A-2B1B-412F-8D72-43273A319CA6</gtr:id><gtr:name>Roche</gtr:name><gtr:address><gtr:line1>PRG Building 93 room 6 10</gtr:line1><gtr:line2>F Hoffman La Roche</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CDA8CCBE-3DD3-481F-97CB-429D6B3601CA"><gtr:id>CDA8CCBE-3DD3-481F-97CB-429D6B3601CA</gtr:id><gtr:name>College of Pharmacy</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C480E383-FDEC-4195-B157-B3A7406325C5"><gtr:id>C480E383-FDEC-4195-B157-B3A7406325C5</gtr:id><gtr:name>College of Sciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/FF9D180E-7AAF-479F-8D6A-91239520D6C2"><gtr:id>FF9D180E-7AAF-479F-8D6A-91239520D6C2</gtr:id><gtr:name>Zoology Ecology and Plant Science</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E68BE577-6C17-48CE-B65C-24C477BB8AE9"><gtr:id>E68BE577-6C17-48CE-B65C-24C477BB8AE9</gtr:id><gtr:name>Yeshiva University</gtr:name><gtr:address><gtr:line1>500 West 185th Street</gtr:line1><gtr:postCode>10033</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DD8042D9-E20B-4415-8883-53B0C63EAC7D"><gtr:id>DD8042D9-E20B-4415-8883-53B0C63EAC7D</gtr:id><gtr:name>Basilea Pharmaceutica</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0B92D4B2-4955-4E0E-A0B8-2511FE3C2422"><gtr:id>0B92D4B2-4955-4E0E-A0B8-2511FE3C2422</gtr:id><gtr:name>Koninklijke Philips Electronics N.V.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/80DD41C8-30F5-4AB5-A2F4-F3285B212F89"><gtr:id>80DD41C8-30F5-4AB5-A2F4-F3285B212F89</gtr:id><gtr:name>Johns Hopkins Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/ED4D1A06-2089-4A05-82E7-CEC2691DC300"><gtr:id>ED4D1A06-2089-4A05-82E7-CEC2691DC300</gtr:id><gtr:name>Scottish Enterprise</gtr:name><gtr:address><gtr:line1>5 Atlantic Quay</gtr:line1><gtr:line2>150 Broomielaw</gtr:line2><gtr:postCode>G2 8LU</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DD567D99-893B-43CA-B141-0C6A3D481748"><gtr:id>DD567D99-893B-43CA-B141-0C6A3D481748</gtr:id><gtr:name>School of Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7D9B4D62-B1BB-4DEC-9664-795B9EC472D7"><gtr:id>7D9B4D62-B1BB-4DEC-9664-795B9EC472D7</gtr:id><gtr:name>School of Medicine Alabama at Birmingham</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1354C618-9C7F-4E90-97AE-2A04B4C8536D"><gtr:id>1354C618-9C7F-4E90-97AE-2A04B4C8536D</gtr:id><gtr:name>Cancer Research UK (CRUK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C6FE58D7-730F-43F0-BAA9-0536B3EEAD2B"><gtr:id>C6FE58D7-730F-43F0-BAA9-0536B3EEAD2B</gtr:id><gtr:name>Queen's University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/931F0B0D-E479-4E31-AF94-5CCAFB6A4445"><gtr:id>931F0B0D-E479-4E31-AF94-5CCAFB6A4445</gtr:id><gtr:name>deCODE Genetics</gtr:name><gtr:address><gtr:line1>Sturlugata 8</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7D75A446-82F4-4F8E-8727-ABB8729B94DE"><gtr:id>7D75A446-82F4-4F8E-8727-ABB8729B94DE</gtr:id><gtr:name>Merck (KGaA)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DA82066A-2B1B-412F-8D72-43273A319CA6"><gtr:id>DA82066A-2B1B-412F-8D72-43273A319CA6</gtr:id><gtr:name>Roche</gtr:name><gtr:address><gtr:line1>PRG Building 93 room 6 10</gtr:line1><gtr:line2>F Hoffman La Roche</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CDA8CCBE-3DD3-481F-97CB-429D6B3601CA"><gtr:id>CDA8CCBE-3DD3-481F-97CB-429D6B3601CA</gtr:id><gtr:name>College of Pharmacy</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C480E383-FDEC-4195-B157-B3A7406325C5"><gtr:id>C480E383-FDEC-4195-B157-B3A7406325C5</gtr:id><gtr:name>College of Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FF9D180E-7AAF-479F-8D6A-91239520D6C2"><gtr:id>FF9D180E-7AAF-479F-8D6A-91239520D6C2</gtr:id><gtr:name>Zoology Ecology and Plant Science</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E68BE577-6C17-48CE-B65C-24C477BB8AE9"><gtr:id>E68BE577-6C17-48CE-B65C-24C477BB8AE9</gtr:id><gtr:name>Yeshiva University</gtr:name><gtr:address><gtr:line1>500 West 185th Street</gtr:line1><gtr:postCode>10033</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DD8042D9-E20B-4415-8883-53B0C63EAC7D"><gtr:id>DD8042D9-E20B-4415-8883-53B0C63EAC7D</gtr:id><gtr:name>Basilea Pharmaceutica</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0B92D4B2-4955-4E0E-A0B8-2511FE3C2422"><gtr:id>0B92D4B2-4955-4E0E-A0B8-2511FE3C2422</gtr:id><gtr:name>Koninklijke Philips Electronics N.V.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/80DD41C8-30F5-4AB5-A2F4-F3285B212F89"><gtr:id>80DD41C8-30F5-4AB5-A2F4-F3285B212F89</gtr:id><gtr:name>Johns Hopkins Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/ED4D1A06-2089-4A05-82E7-CEC2691DC300"><gtr:id>ED4D1A06-2089-4A05-82E7-CEC2691DC300</gtr:id><gtr:name>Scottish Enterprise</gtr:name><gtr:address><gtr:line1>5 Atlantic Quay</gtr:line1><gtr:line2>150 Broomielaw</gtr:line2><gtr:postCode>G2 8LU</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DD567D99-893B-43CA-B141-0C6A3D481748"><gtr:id>DD567D99-893B-43CA-B141-0C6A3D481748</gtr:id><gtr:name>School of Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7D9B4D62-B1BB-4DEC-9664-795B9EC472D7"><gtr:id>7D9B4D62-B1BB-4DEC-9664-795B9EC472D7</gtr:id><gtr:name>School of Medicine Alabama at Birmingham</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1354C618-9C7F-4E90-97AE-2A04B4C8536D"><gtr:id>1354C618-9C7F-4E90-97AE-2A04B4C8536D</gtr:id><gtr:name>Cancer Research UK (CRUK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C6FE58D7-730F-43F0-BAA9-0536B3EEAD2B"><gtr:id>C6FE58D7-730F-43F0-BAA9-0536B3EEAD2B</gtr:id><gtr:name>Queen's University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/931F0B0D-E479-4E31-AF94-5CCAFB6A4445"><gtr:id>931F0B0D-E479-4E31-AF94-5CCAFB6A4445</gtr:id><gtr:name>deCODE Genetics</gtr:name><gtr:address><gtr:line1>Sturlugata 8</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7D75A446-82F4-4F8E-8727-ABB8729B94DE"><gtr:id>7D75A446-82F4-4F8E-8727-ABB8729B94DE</gtr:id><gtr:name>Merck (KGaA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/599807B2-C178-45E6-8C5F-7A6617273BD5"><gtr:id>599807B2-C178-45E6-8C5F-7A6617273BD5</gtr:id><gtr:firstName>Miles</gtr:firstName><gtr:otherNames>Douglas</gtr:otherNames><gtr:surname>Houslay</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/365AE3B7-F093-48B1-83B3-35E085126B4A"><gtr:id>365AE3B7-F093-48B1-83B3-35E085126B4A</gtr:id><gtr:firstName>George</gtr:firstName><gtr:otherNames>Scott</gtr:otherNames><gtr:surname>Baillie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0600765"><gtr:id>88134DE9-A523-4A6C-9E1B-1B2A459E9AF4</gtr:id><gtr:title>Phosphodiesterase-4 isoforms: intracellular targeting, regulation and potential therapeutic targets</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0600765</gtr:grantReference><gtr:abstractText>Chronic Obstructive Pulmonary Disease is the fourth leading cause of death in the world. It causes lung damage through chronic inflammation. Raising the levels of a substance called cAMP inside lung cells can stop this. Potential new medicines are drugs that bind tightly to PDE4 enzymes to stop them breaking down cAMP. Unfortunately these drugs cause nausea and vomiting, preventing their use. We?ve found that there are many PDE4 subtypes but that only certain of these need to be inhibited to stop inflammation. We aim to devise novel ways to inhibit these important PDE4 subtypes, rather than all PDE4 enzymes, in order to produce effective medicines with minimal or no side-effects. To do this we will exploit our discovery that individual PDE4 subtypes have unique ?postcodes? built into them that allow them to be targeted to exactly the right place in cells for them to do their job properly. Our aim is to find molecules that block this correct targeting so as to stop them working properly, providing new COPD medicines. As our drugs focus on just the PDE4 subtype involved in COPD they should not have the side effects caused by current drugs that inhibit all PDE4 subtypes.</gtr:abstractText><gtr:technicalSummary>cAMP is a pivotal second messenger able to exert a panoply of cell type specific effects. A multigene family of phosphodiesterases (PDEs) provide the sole means for degrading cAMP and are thus poised to play a key regulatory role in cells. Highly specialised regulatory properties, coupled with cell specific patterns of expression, provide each cell type with a sophisticated and unique means of regulating intracellular cAMP through PDE action. This diversity offers potential for developing highly specific therapeutic agents. There is great interest in developing PDE4 family selective inhibitors for treating Chronic Obstructive Pulmonary Disease (COPD), asthma and other diseases. However, the therapeutic deployment of PDE4 inhibitors has been limited by side effects, such as nausea. It is now appreciated that PDE4 activity is attributable to a large family of isoforms. This has prompted the notion that selective inhibition of particular PDE4 isoforms may maximise therapeutic benefit whilst minimising side effects. Four PDE4 genes produce around 20 isoforms that each have a unique N terminal region and either both UCR1/2 or just UCR2 regulatory domains. Individual PDE4 isoforms have unique functional roles that are attributable to defined intracellular targeting / association with protein complexes. This provides a major underpinning of compartmentalised cAMP signalling. We aim to determine the functional role and basis by which the N terminal and UCR1/2 tailor intracellular targeting, interaction with signal scaffold proteins and regulation by phosphorylation of specific PDE4 isoforms. Our studies have implications for the identification of novel means of generating inhibitors selective for specific PDE4 isoforms by preventing specific PDE4 isoforms from being targeted to their functionally relevant sites in cells. This provides a route to overcome problems in making effective isoform-selective inhibitors by traditional means, namely directed at the active site, as the PDE4 catalytic unit is identical within PDE4 sub-families &amp;amp; very similar between them. Identification of PDE4 interacting proteins has potential for identifying novel biomarkers for COPD. Analysis of post-translational modification of isoforms has potential for appreciating aberrant control of specific PDE4 isoforms in disease. In particular we will focus on (i) PDE4A4, which is selectively up-regulated in COPD macrophages; (ii) PDE4B2, which has been implicated as of importance in regulating macrophage functioning; (iii) PDE4D5, which is up-regulated in macrophages of smokers, regulates beta2AR functioning through beta-arrestin sequestration and is induced by hypoxia in smooth muscle cells and (iv) PDE4D3, which is the major PDE4 in monocytes.</gtr:technicalSummary><gtr:fund><gtr:end>2012-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1852991</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Medicine Alabama at Birmingham</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Radiation Oncology</gtr:department><gtr:description>PDE4 dimerisation</gtr:description><gtr:id>46917D46-ACB8-4192-A05C-C6C60363D56B</gtr:id><gtr:impact>Publications being written up.
Impact on understanding the dynamics of PDE4 partnerships in cells. 
Impact on understanding selective inhibition</gtr:impact><gtr:partnerContribution>Yeast 2-hybrid expertise; generated mutants</gtr:partnerContribution><gtr:piContribution>Led study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>College of Sciences</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Biology</gtr:department><gtr:description>Small molecule PDE4 subfamily inhibitors</gtr:description><gtr:id>3EBA5D85-1CD6-42B6-AA5B-BF00E3B8D069</gtr:id><gtr:impact>developing molecules for publication / IP</gtr:impact><gtr:partnerContribution>provision of small molecule PDE inhibitors from a novel yeast-based screen</gtr:partnerContribution><gtr:piContribution>provision of pde4 sub-family specific assay systems
provision of cell-based cell systems for anti-inflammatory analyses
project development</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck (KGaA)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Millipore</gtr:department><gtr:description>PDE4 antisera and cell lines</gtr:description><gtr:id>744311D0-D7BE-49A3-84ED-51D27A27CDA3</gtr:id><gtr:impact>Jointly generating antisera to PDE4 isoforms and sub-families. We are supplying know-how and testing; they are generating the antisera and cell lines. Our lab has received 16000 GBP to offset costs plus a share in the reagents generated and Univ Glasgow will obtain a share in royalties for any sales</gtr:impact><gtr:partnerContribution>Jointly generating antisera to PDE4 isoforms and sub-families. We are supplying know-how and testing; they are generating the antisera and cell lines. Our lab has received 16000 GBP to offset costs plus a share in the reagents generated and Univ Glasgow will obtain a share in royalties for any sales</gtr:partnerContribution><gtr:piContribution>Jointly generating antisera to PDE4 isoforms and sub-families. We are supplying know-how and testing; they are generating the antisera and cell lines. Our lab has received 16000 GBP to offset costs plus a share in the reagents generated and Univ Glasgow will obtain a share in royalties for any sales</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oslo</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Biotechnology Centre of Oslo</gtr:department><gtr:description>T-cell receptor activation in human primary T cells</gtr:description><gtr:id>D840D861-E925-4FC2-8C7C-D91A674F3C8E</gtr:id><gtr:impact>Publications</gtr:impact><gtr:partnerContribution>Provided access to a novel system for analyses</gtr:partnerContribution><gtr:piContribution>Identification of a novel complex of beta-arretsin/PDE4/Akt regukated by CD28 that controls T-cell receptor activation. Mapping sites, defining function.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Koninklijke Philips Electronics N.V.</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>Philips</gtr:department><gtr:description>cAMP signalling in prostate cancer</gtr:description><gtr:id>5EBEB25F-BED0-469B-86D7-DE1F77D64CDF</gtr:id><gtr:impact>Studentship support. 
Has provided new insights and indicated new directions plus access to novel technologies. 
Has led to three patent applications</gtr:impact><gtr:partnerContribution>Studentship support. Has provided new insights and indicated new directions plus access to novel technologies.</gtr:partnerContribution><gtr:piContribution>I supervise a research student who works full-time in my laboratory. My team provide underpinning expertise of cAMP phosphodiesterases.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK (CRUK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Edinburgh Cancer Research UK Centre</gtr:department><gtr:description>PDE4D5 and FAK:RACK1 complexes in direction sensing complexes</gtr:description><gtr:id>8C44DE61-814F-4E63-A5EE-6A25F9D98F81</gtr:id><gtr:impact>Publication.
We are developing small molecules / peptide disruptors as potential therapeutics</gtr:impact><gtr:partnerContribution>Provison of a novel system to explore the functional role of our RACK1:PDE4D5 complex</gtr:partnerContribution><gtr:piContribution>we describe a novel &amp;quot;direction-sensing&amp;quot; pathway that links the integrin effector focal adhesion kinase (FAK), the molecular scaffold protein RACK1, and activity of one of its client proteins, PDE4D5, a cAMP-degrading phosphodiesterase. 
we identified the key complexes, mapped the interaction surfaces and developed disruptors</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>College of Pharmacy</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Medicinal Chemistry and Molecular Pharmacology</gtr:department><gtr:description>Reverse transcriptase inhibitor actions on PDE4</gtr:description><gtr:id>E5A86501-928C-4EB2-88AC-A00E2D165280</gtr:id><gtr:impact>Publications</gtr:impact><gtr:partnerContribution>Provison of small molecules for analyses in our Labs</gtr:partnerContribution><gtr:piContribution>Analsysi of small molecules in various PDE4 assay systems</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johns Hopkins Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Psychiatry and Behavioral Sciences</gtr:department><gtr:description>DISC1 partnerships</gtr:description><gtr:id>7BA978AF-0AAF-4472-9D6E-8971C05204D3</gtr:id><gtr:impact>Publications</gtr:impact><gtr:partnerContribution>novel in vivo system access
novel system for analysing the PDE4 partner, DISC1</gtr:partnerContribution><gtr:piContribution>Project development.
Protein-protein mapping
reagent generation
DISC1 expression</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Basilea Pharmaceutica</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>PDE4 selective Inhibitors</gtr:description><gtr:id>9563CA0F-3806-4D8A-B74F-8FB0441AC028</gtr:id><gtr:impact>We have received funds to analyse novel PDE4 inhibitors with a view to furthering interactions should the company continue work in this new area.</gtr:impact><gtr:partnerContribution>Supply of novel inhibitors</gtr:partnerContribution><gtr:piContribution>We have received funds to analyse novel PDE4 inhibitors with a view to potential further interactions with the company.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College Cork</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:department>BioSciences Institute</gtr:department><gtr:description>RACK1 signalling functions</gtr:description><gtr:id>FC267DE6-A5B2-40F5-A621-E1B084C64F1C</gtr:id><gtr:impact>Publications
Peptide disruptor development.</gtr:impact><gtr:partnerContribution>Expertise in FAK; novel cell / in vivo systems.</gtr:partnerContribution><gtr:piContribution>Defining protein protein interactions with peptide arays; generating mutants;</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Medicine (UPenn)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Neuroscience</gtr:department><gtr:description>PDE4A and sleep</gtr:description><gtr:id>9206D0CB-A1A8-4802-A26F-C73A5E589D29</gtr:id><gtr:impact>Publications</gtr:impact><gtr:partnerContribution>Publications.
Access to in vivo analyses</gtr:partnerContribution><gtr:piContribution>Project management
Analsysis of PDE4 activity and expression
Provision of reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Scottish Enterprise</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Stem Cells</gtr:description><gtr:id>2C322659-887F-4DF3-AF6F-7C4437D5FCB0</gtr:id><gtr:impact>PDE2 inhibitor, Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) found to block differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. this has led to a patent</gtr:impact><gtr:partnerContribution>provided stem cell know how and various state of the art pieces of equipment</gtr:partnerContribution><gtr:piContribution>PDE know how</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Pharmacology</gtr:department><gtr:description>Sub-plasmalemma cAMP compartments</gtr:description><gtr:id>357B839C-A3EE-42A1-B8AE-F323EAFDA02D</gtr:id><gtr:impact>Publications</gtr:impact><gtr:partnerContribution>Novel system for understanding PDE4 function</gtr:partnerContribution><gtr:piContribution>Joint project development.
Novel reagents: cDNA constructs, antisera
Dominant neative PDE4 approach</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Pharmacology</gtr:department><gtr:description>Cardiac IKs K+ channel</gtr:description><gtr:id>89D6B77C-7B2B-437C-90BD-6E95FAD57EC5</gtr:id><gtr:impact>Publications</gtr:impact><gtr:partnerContribution>Identification of a novel system where PDE4 is involved</gtr:partnerContribution><gtr:piContribution>Project development
Reagent provision.
Mapping protein-protein interfaces with peptide arrays.
Development of mutant PDE4 species.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's University</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Department of Pathology &amp; Molecular Medicine</gtr:department><gtr:description>PDE4 and vascular permeability</gtr:description><gtr:id>8757BF08-F6C6-40B9-B92E-B98026A5DF17</gtr:id><gtr:impact>Publications</gtr:impact><gtr:partnerContribution>Joint project management.
Access to unique in vivo models</gtr:partnerContribution><gtr:piContribution>Project management
PDE4 activity and expression analyses</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Roche</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Memory Pharmaceuticals</gtr:department><gtr:description>Identification of PDE4A8, a novel cAMP phosphodiesterase</gtr:description><gtr:id>D2C35371-F37B-4AFF-A7C8-8FFB36B6C3AA</gtr:id><gtr:impact>Contributed experimental research work for a joint publication involved in the identification and characterisation of a novel cAMP phosphodiesterase.; Allowed us access to a novel PDE4A clone without having to generate it ourself. Given access to a company that may lead to future collaborations. Created useful contacts.</gtr:impact><gtr:partnerContribution>Allowed us access to a novel PDE4A clone without having to generate it ourselves. Created useful contacts.</gtr:partnerContribution><gtr:piContribution>Allowed us access to a novel PDE4A clone without having to generate it ourselves. Created useful contacts.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>deCODE genetics</gtr:collaboratingOrganisation><gtr:country>Iceland, Republic of</gtr:country><gtr:description>Novel allosteric regulators of PDE4</gtr:description><gtr:id>118F5BF3-77BC-455F-85F4-2890EED91C1F</gtr:id><gtr:impact>Allowed us access to novel PDE4 inhibitors, to novel structural data and to purified PDE4 proteins with possibility for joint research/publication and future funding.</gtr:impact><gtr:partnerContribution>Allowed us access to novel PDE4 inhibitors, to novel structural data and to purified PDE4 proteins with possibility for joint research/publication and future funding.</gtr:partnerContribution><gtr:piContribution>Analyzed the effect of a novel PDE4 selective inhibitor in one of our assays systems to determine if there was potential for collaboration. deCode has since gone into chapter 11 bankruptcy so the project could not continue.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albert Einstein College of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Molecular Pharmacology</gtr:department><gtr:description>PDE and immunosuppression</gtr:description><gtr:id>6787AA25-F97F-4E47-9F5E-9CF23293AF44</gtr:id><gtr:impact>Publications
Novel reagents</gtr:impact><gtr:partnerContribution>Identification of a novel system where PDE4 is involved</gtr:partnerContribution><gtr:piContribution>Joint project management
PDE4 reagents
PDE4 analsyes
Ubiquitin ananlsyes
Peptide mapping</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Psychiatry Pfizer</gtr:department><gtr:description>PDE in Psychiatric disease</gtr:description><gtr:id>B29C4E13-70E6-4080-92A3-973DF2E6D60F</gtr:id><gtr:impact>Publications
Imminent signing of a contract for PDE4:DISC1 research</gtr:impact><gtr:partnerContribution>reagents
access to novel in vivo systems</gtr:partnerContribution><gtr:piContribution>Expertsie on PDEs
Reagents
Anayses of PDE actiity and expression
Peptide mapping</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Alumni letter</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0EFDEC8A-CFC3-4021-8578-24EEAAC9CF68</gtr:id><gtr:impact>described life as a biomedical scientist

hopefully interested people as received feedback</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sleep Radio Broadcast</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DE26FE15-3D23-48FB-9299-C2EC4B67C8F5</gtr:id><gtr:impact>Radio broadcast interview

Email contact from members of public. Contact from clinicians involved in sleep research</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Festival Event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>363DDF04-2AAD-4B6A-91FB-7DB80A00F3DD</gtr:id><gtr:impact>Manning of a stand at a science festival event for schools. Continual flow of pupils though.

Enquiries form students about courses and careers</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School - Renfrewshire</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DCFD398E-9778-4C70-9A5E-25CC901C36E7</gtr:id><gtr:impact>Talk on research in signaling systems and biomedical impact.

Hopefully increased applications to study biomedical sciences</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sleep press release</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6DB85F3E-24EB-4FA5-BEAD-E3C3F4AA734E</gtr:id><gtr:impact>press release on use of PDE4 inhibitors for correcting cognitive defects upon sleep deprivation.

request for information from various journalists and members of the public.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>322000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant (co-PI)</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>B9E8A12F-FADB-422E-8B11-3ECC6F801BEE</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Transatlantic Network of Excellence (co-PI)</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Transatlantic Networks of Excellence in Cardiovascular Research Program</gtr:fundingOrg><gtr:id>4C184C04-5DDF-4737-A95A-1D9AF3DB53DE</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>222000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>FP6 (co-PI)</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>7AB1F5B5-16D6-41F6-9E85-09B4126276B4</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>208000</gtr:amountPounds><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Excellence (co-PI)/Center for Translational Molecular Medicine (Netherlands)</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Center for Translational Molecular Medicine (CTMM)</gtr:fundingOrg><gtr:id>BEF4EF46-8B68-46C1-916F-D24924178C89</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>PDE PCR panel as a diagnsotic tool for prostate cancer</gtr:description><gtr:id>69B215FE-9B77-43C3-B128-EED0DE90E3CC</gtr:id><gtr:impact>Expected to lead to major publications</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2010131194</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>PDE expression profliing 3</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>PDE9 expression profiling as a diagnostic indicator for stages of prostate cancer</gtr:description><gtr:id>B18E928D-3407-42DB-95A0-98ED4FCA595F</gtr:id><gtr:impact>Exepcted to lead to major publciations</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2010131193</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>PDE expression profliing 2</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>We have discovered a novel way of blocking the spontaneous differentiation of hESCs in the absence of exogenous cytokines by supplementing feeder-free conditions with erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), an established inhibitor of cyclic nucleotide phosphodiesterase- 2 (PDE2).</gtr:description><gtr:id>FA117A98-361D-42D1-A13B-AB2E94B924B7</gtr:id><gtr:impact>generated a publication. enhanced career prospects of involved scientists</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2010084300</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>STEM CELL CULTURE METHODS</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>PDE4D7 expression profiling as a diagnostic indicator for stages of prostate cancer</gtr:description><gtr:id>A9052D80-605E-4779-8FFC-5807E17F247D</gtr:id><gtr:impact>Expected to lead to major publications</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2010131195</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>PDE expression profiling 1</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Marketing being developed by Millipore</gtr:description><gtr:id>8CFF5B88-86DA-42C7-8D34-624A6B4DF3E0</gtr:id><gtr:impact>Will provide a novel platform for development of PDE4 selective therapeutics to treat inflammatory disease.</gtr:impact><gtr:stage>Market authorisation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PDE4 stable cell lines</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>A panel of antisera specifc for PDE4 sub-fmailies and specific PDE4 isoforms. Now fully developed and marketing being assessed by Milipore.</gtr:description><gtr:id>0C9C7B74-A137-4B28-8D1B-0C5C2ABE459C</gtr:id><gtr:impact>Will provide our group with access to first rate diagnostic reagents essential for our research. 
Will provide the research community with the same high quality reagents.</gtr:impact><gtr:stage>Market authorisation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PDE4 antibody panel</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:url>http://www.antibodypedia.com/gene/4321/PDE4A/antibody/555536/ABS23</gtr:url><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A cell permeable peptide that disrupts the association of PDE4D5 with beta-arrestin and so promulgates beta2-adrenoceptor signalling.</gtr:description><gtr:id>9421B32E-933B-4B66-9573-74AD7143E8C2</gtr:id><gtr:impact>PDE4 inhibitors have potential utility in asthma and COPD but their deployment has been hindered due to side effects of emesis because active-site directed inhibitors act on all 25+ isoforms. This technology shows that disrupting the targeting of a specific disease-associated isoform can lead to the 'functional' inhibition of a single species. This addresses the PDE4D5 isoform, which regulates beta2-adrenoceptor signalling and causes resistance to the action of beta2 agonists used in asthma treatment as it is up-regulated with their chronic use. Our data suggests that the development of peptidomimetics or small molecules that disrupt the association of PDE4D5 with beta-arrestin will promulgate beta2-adrenoceptor signalling and so could be used in cases of beta2-agonist (eg salbutamol) resistant patients.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PDE4/beta-arrestin peptide disruptor</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Spot immobilized peptide arrays used for in vitro ubiquitination in order to determine potential sites of modification.</gtr:description><gtr:id>986FF89B-76F4-4AFF-A470-FAB940094C21</gtr:id><gtr:impact>Has potential for rapid and cheap site identification that otherwise would have to be undertaken by exhaustive and expensive mutagenesis.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mapping of potential ubiquitination sites</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>antisera specific for PDE4 subfamilies and various PDE4 isoforms</gtr:description><gtr:id>8CEC4318-63E9-4A34-B803-9AB351251152</gtr:id><gtr:impact>High quality antisera developed both by ourselves and in collaboration with Millipore to aid our work and that of the academic community.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PDE4 antisera</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Use of EPAC agonists to promulgate the nuclear exit of DNA-PKc.</gtr:description><gtr:id>CB3AA87E-E8CE-41CC-B96A-7F0DF70F86F1</gtr:id><gtr:impact>1. Suggests the potential therapeutic use of EPAC agonists as radio- or chemo-sensitizers by removing DNA-PKc from the nucleus and so hindering repair of double stranded breaks. 2. First identification of a mechanism where cAMP provides dual inhibitory and stimulatory inputs through different effectors.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>DNA-PK nuclear-cytoplasmic trafficking</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have shown that PDE expression profiling can provide a potential diagnostic indicator for different stages of prostate cancer.</gtr:description><gtr:id>D472122F-B5F3-447C-96DA-621AF2840585</gtr:id><gtr:impact>This has led to three patents being filed.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PDE expression profiling</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/55DFBB0B-998F-4F3E-82A4-7F1E560962A5"><gtr:id>55DFBB0B-998F-4F3E-82A4-7F1E560962A5</gtr:id><gtr:title>PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases.</gtr:title><gtr:parentPublicationTitle>Handbook of experimental pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0c04fe0beea4e97f9253297a2a02b423"><gtr:id>0c04fe0beea4e97f9253297a2a02b423</gtr:id><gtr:otherNames>McCahill AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0171-2004</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/094BF1D7-1D36-4C24-B167-00C2A69A2BF6"><gtr:id>094BF1D7-1D36-4C24-B167-00C2A69A2BF6</gtr:id><gtr:title>Protein kinase A type I and type II define distinct intracellular signaling compartments.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/865700af3571997547810922ba2a0b9c"><gtr:id>865700af3571997547810922ba2a0b9c</gtr:id><gtr:otherNames>Di Benedetto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0F1D4DE6-D8F8-42C9-9B37-A4D40EF5649C"><gtr:id>0F1D4DE6-D8F8-42C9-9B37-A4D40EF5649C</gtr:id><gtr:title>Cross talk between phosphatidylinositol 3-kinase and cyclic AMP (cAMP)-protein kinase a signaling pathways at the level of a protein kinase B/beta-arrestin/cAMP phosphodiesterase 4 complex.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8d0157f49a10867cb144a2c597d758b1"><gtr:id>8d0157f49a10867cb144a2c597d758b1</gtr:id><gtr:otherNames>Bj?rgo E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B6F8DA7D-A22A-42C3-B3BE-4A013BDFE46B"><gtr:id>B6F8DA7D-A22A-42C3-B3BE-4A013BDFE46B</gtr:id><gtr:title>EPAC and PKA allow cAMP dual control over DNA-PK nuclear translocation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ecf4cd9acb13c24315858961d0ffcd3d"><gtr:id>ecf4cd9acb13c24315858961d0ffcd3d</gtr:id><gtr:otherNames>Huston E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3EF4E1BB-7533-40DC-849B-2CE3047A9F8A"><gtr:id>3EF4E1BB-7533-40DC-849B-2CE3047A9F8A</gtr:id><gtr:title>A phosphodiesterase 3B-based signaling complex integrates exchange protein activated by cAMP 1 and phosphatidylinositol 3-kinase signals in human arterial endothelial cells.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9d5bd86d56dc05ee8c86d0a1b2b00c0a"><gtr:id>9d5bd86d56dc05ee8c86d0a1b2b00c0a</gtr:id><gtr:otherNames>Wilson LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CFD6C4E0-79CD-4337-B466-14A65E111453"><gtr:id>CFD6C4E0-79CD-4337-B466-14A65E111453</gtr:id><gtr:title>Cyclic AMP phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a vascular endothelial cadherin (VE-Cad)-based signaling complex and controls cAMP-mediated vascular permeability.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d09fbce6b9001841403e81d2762b3f70"><gtr:id>d09fbce6b9001841403e81d2762b3f70</gtr:id><gtr:otherNames>Rampersad SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1FDB399C-D008-4D00-A0F6-005D7E47831C"><gtr:id>1FDB399C-D008-4D00-A0F6-005D7E47831C</gtr:id><gtr:title>Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)-HSP20 complex attenuates the ?-agonist induced hypertrophic response in cardiac myocytes.</gtr:title><gtr:parentPublicationTitle>Journal of molecular and cellular cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e3671a59fe7ec7112c44b200ff68dea5"><gtr:id>e3671a59fe7ec7112c44b200ff68dea5</gtr:id><gtr:otherNames>Sin YY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2828</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2116D1C6-E22B-4FF2-A0D4-2DED8E2BD69C"><gtr:id>2116D1C6-E22B-4FF2-A0D4-2DED8E2BD69C</gtr:id><gtr:title>Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/93f8556619f3487d06c35513ec7d86fb"><gtr:id>93f8556619f3487d06c35513ec7d86fb</gtr:id><gtr:otherNames>Li X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/271A8B65-D904-4FFA-86A3-7CCE79ECE116"><gtr:id>271A8B65-D904-4FFA-86A3-7CCE79ECE116</gtr:id><gtr:title>Evolutionarily conserved role of calcineurin in phosphodegron-dependent degradation of phosphodiesterase 4D.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c26722ea1361991f09651c3954b807a7"><gtr:id>c26722ea1361991f09651c3954b807a7</gtr:id><gtr:otherNames>Zhu H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F46431C7-9B53-4D9F-A4D2-5C80AB2A98AD"><gtr:id>F46431C7-9B53-4D9F-A4D2-5C80AB2A98AD</gtr:id><gtr:title>A scanning peptide array approach uncovers association sites within the JNK/beta arrestin signalling complex.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/93f8556619f3487d06c35513ec7d86fb"><gtr:id>93f8556619f3487d06c35513ec7d86fb</gtr:id><gtr:otherNames>Li X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5D52488F-34D6-4173-8385-73C55D2B3D7A"><gtr:id>5D52488F-34D6-4173-8385-73C55D2B3D7A</gtr:id><gtr:title>DISC1-dependent switch from progenitor proliferation to migration in the developing cortex.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bf8f92044b07e66764171b2fa4bce1d8"><gtr:id>bf8f92044b07e66764171b2fa4bce1d8</gtr:id><gtr:otherNames>Ishizuka K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7506873D-33CA-4D9C-BF64-030780D6B9AE"><gtr:id>7506873D-33CA-4D9C-BF64-030780D6B9AE</gtr:id><gtr:title>Targeting protein-protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease.</gtr:title><gtr:parentPublicationTitle>Future medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4e89a3b960dfe0dd56530310b4ce40a9"><gtr:id>4e89a3b960dfe0dd56530310b4ce40a9</gtr:id><gtr:otherNames>Lee LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1756-8919</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/62FB15EF-A4C5-4AC6-AF12-CDE1DCB63478"><gtr:id>62FB15EF-A4C5-4AC6-AF12-CDE1DCB63478</gtr:id><gtr:title>Gravin orchestrates protein kinase A and ?2-adrenergic receptor signaling critical for synaptic plasticity and memory.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e97d2ee215aebc3a5195e09cf65db848"><gtr:id>e97d2ee215aebc3a5195e09cf65db848</gtr:id><gtr:otherNames>Havekes R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/85332A3A-EC89-486A-ABDD-6B42B5E4C91F"><gtr:id>85332A3A-EC89-486A-ABDD-6B42B5E4C91F</gtr:id><gtr:title>Mdm2 directs the ubiquitination of beta-arrestin-sequestered cAMP phosphodiesterase-4D5.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/93f8556619f3487d06c35513ec7d86fb"><gtr:id>93f8556619f3487d06c35513ec7d86fb</gtr:id><gtr:otherNames>Li X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/96E3721B-63BC-4E62-9982-7B0D8D3C204B"><gtr:id>96E3721B-63BC-4E62-9982-7B0D8D3C204B</gtr:id><gtr:title>Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/640697cd7d418484c285b7ec0d4219e8"><gtr:id>640697cd7d418484c285b7ec0d4219e8</gtr:id><gtr:otherNames>Christian F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B0D25055-3C04-41CE-B538-711F27EB1CCD"><gtr:id>B0D25055-3C04-41CE-B538-711F27EB1CCD</gtr:id><gtr:title>Constitutive activation of the G-protein subunit Galphas within forebrain neurons causes PKA-dependent alterations in fear conditioning and cortical Arc mRNA expression.</gtr:title><gtr:parentPublicationTitle>Learning &amp; memory (Cold Spring Harbor, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d68d9d60dc03e9488b19d262c79dce20"><gtr:id>d68d9d60dc03e9488b19d262c79dce20</gtr:id><gtr:otherNames>Kelly MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1072-0502</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4F57FBAB-AEC4-47FF-B581-8BCCA45EF3FB"><gtr:id>4F57FBAB-AEC4-47FF-B581-8BCCA45EF3FB</gtr:id><gtr:title>Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/03013947ed624d1193a4f60253886034"><gtr:id>03013947ed624d1193a4f60253886034</gtr:id><gtr:otherNames>Burton P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EDBE28E6-4E7E-48F4-81B9-BADE5A15AB49"><gtr:id>EDBE28E6-4E7E-48F4-81B9-BADE5A15AB49</gtr:id><gtr:title>Regulation of a Drosophila melanogaster cGMP-specific phosphodiesterase by prenylation and interaction with a prenyl-binding protein.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7d46a299510bcbef6c0115bee738cd56"><gtr:id>7d46a299510bcbef6c0115bee738cd56</gtr:id><gtr:otherNames>Day JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/16B389A3-59A8-4751-AB6C-26AB4866A0BD"><gtr:id>16B389A3-59A8-4751-AB6C-26AB4866A0BD</gtr:id><gtr:title>The emerging role of HSP20 as a multifunctional protective agent.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a0341c4ef012fdc6d1bef37517bb1fa9"><gtr:id>a0341c4ef012fdc6d1bef37517bb1fa9</gtr:id><gtr:otherNames>Edwards HV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B1617FCB-BAA1-47CC-BDDC-EF3EC0C504E2"><gtr:id>B1617FCB-BAA1-47CC-BDDC-EF3EC0C504E2</gtr:id><gtr:title>Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA).</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2716b4ee31bcde99145fdb38ebfc335f"><gtr:id>2716b4ee31bcde99145fdb38ebfc335f</gtr:id><gtr:otherNames>Collins DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/17C53EDC-AE5D-4469-9FA9-D14690A99998"><gtr:id>17C53EDC-AE5D-4469-9FA9-D14690A99998</gtr:id><gtr:title>cAMP-specific phosphodiesterase-4D5 (PDE4D5) provides a paradigm for understanding the unique non-redundant roles that PDE4 isoforms play in shaping compartmentalized cAMP cell signalling.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/676166fcb358e638222e71174647935b"><gtr:id>676166fcb358e638222e71174647935b</gtr:id><gtr:otherNames>Lynch MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E9D68D70-9C56-4CE9-B032-2BE6E1ADF6CF"><gtr:id>E9D68D70-9C56-4CE9-B032-2BE6E1ADF6CF</gtr:id><gtr:title>?-Arrestin 1 inhibits the GTPase-activating protein function of ARHGAP21, promoting activation of RhoA following angiotensin II type 1A receptor stimulation.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8b2cb02f8edc9566bc256206b1518256"><gtr:id>8b2cb02f8edc9566bc256206b1518256</gtr:id><gtr:otherNames>Anthony DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/41918918-D713-4BA4-AF51-C84E30583EF5"><gtr:id>41918918-D713-4BA4-AF51-C84E30583EF5</gtr:id><gtr:title>Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/96b40aa5de27031cfad4d0acc4814787"><gtr:id>96b40aa5de27031cfad4d0acc4814787</gtr:id><gtr:otherNames>MacKenzie KF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6E6B702D-1147-4B63-98CA-F0FBCE439FF6"><gtr:id>6E6B702D-1147-4B63-98CA-F0FBCE439FF6</gtr:id><gtr:title>p75 Neurotrophin Receptor Regulates Energy Balance in Obesity.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9bc0f04f96a32f94af6b9e2eb3a012f9"><gtr:id>9bc0f04f96a32f94af6b9e2eb3a012f9</gtr:id><gtr:otherNames>Baeza-Raja B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C7385EE8-A03B-4282-86A9-9A4A12971F65"><gtr:id>C7385EE8-A03B-4282-86A9-9A4A12971F65</gtr:id><gtr:title>The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5d31fb9bf243eab3552f8fc30102ef2a"><gtr:id>5d31fb9bf243eab3552f8fc30102ef2a</gtr:id><gtr:otherNames>Ong WK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2DA3EC7F-5E41-4417-BEA8-954C52434765"><gtr:id>2DA3EC7F-5E41-4417-BEA8-954C52434765</gtr:id><gtr:title>Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/68e131f4e73386b42f4a019c05ee6cea"><gtr:id>68e131f4e73386b42f4a019c05ee6cea</gtr:id><gtr:otherNames>Baillie GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/629FB8B2-F8EA-4268-A156-E61B01DC0ECE"><gtr:id>629FB8B2-F8EA-4268-A156-E61B01DC0ECE</gtr:id><gtr:title>PKA phosphorylation of p62/SQSTM1 regulates PB1 domain interaction partner binding.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/640697cd7d418484c285b7ec0d4219e8"><gtr:id>640697cd7d418484c285b7ec0d4219e8</gtr:id><gtr:otherNames>Christian F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E6CCC4DC-B938-4AE3-943F-95D346DE11A8"><gtr:id>E6CCC4DC-B938-4AE3-943F-95D346DE11A8</gtr:id><gtr:title>Inferring signaling pathway topologies from multiple perturbation measurements of specific biochemical species.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bcc2284555def528ab993e8adea04d60"><gtr:id>bcc2284555def528ab993e8adea04d60</gtr:id><gtr:otherNames>Xu TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C862DC1-C9DD-4EFA-8C09-E335397CC382"><gtr:id>3C862DC1-C9DD-4EFA-8C09-E335397CC382</gtr:id><gtr:title>1H NMR structural and functional characterisation of a cAMP-specific phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that disrupts PDE4D5 interaction with the signalling scaffold proteins, beta-arrestin and RACK1.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fbc394f2c999ae55bf9195e61fb2a23a"><gtr:id>fbc394f2c999ae55bf9195e61fb2a23a</gtr:id><gtr:otherNames>Smith KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6CA1ABC4-21C1-4B44-BD74-71CA96BE74B5"><gtr:id>6CA1ABC4-21C1-4B44-BD74-71CA96BE74B5</gtr:id><gtr:title>cAMP: novel concepts in compartmentalised signalling.</gtr:title><gtr:parentPublicationTitle>Seminars in cell &amp; developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a0341c4ef012fdc6d1bef37517bb1fa9"><gtr:id>a0341c4ef012fdc6d1bef37517bb1fa9</gtr:id><gtr:otherNames>Edwards HV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1084-9521</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2A666EB3-77DC-4029-8147-323B1E27ED7D"><gtr:id>2A666EB3-77DC-4029-8147-323B1E27ED7D</gtr:id><gtr:title>Inferring signaling pathway topologies from multiple perturbation measurements of specific biochemical species.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bcc2284555def528ab993e8adea04d60"><gtr:id>bcc2284555def528ab993e8adea04d60</gtr:id><gtr:otherNames>Xu TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F23A7D72-9598-4530-A7DE-731B922DC2AC"><gtr:id>F23A7D72-9598-4530-A7DE-731B922DC2AC</gtr:id><gtr:title>p62 (SQSTM1) and cyclic AMP phosphodiesterase-4A4 (PDE4A4) locate to a novel, reversible protein aggregate with links to autophagy and proteasome degradation pathways.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/640697cd7d418484c285b7ec0d4219e8"><gtr:id>640697cd7d418484c285b7ec0d4219e8</gtr:id><gtr:otherNames>Christian F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3142EA0B-6BC4-41A2-AD41-295BF5AB2381"><gtr:id>3142EA0B-6BC4-41A2-AD41-295BF5AB2381</gtr:id><gtr:title>p62 (SQSTM1) forms part of a novel, reversible aggregate containing a specific conformer of the cAMP degrading phosphodiesterase, PDE4A4.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0e56f4d61095980aaabb017d2aa7616e"><gtr:id>0e56f4d61095980aaabb017d2aa7616e</gtr:id><gtr:otherNames>Houslay MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9D6749F2-2F93-4D67-910C-2B7D8FDAC2C3"><gtr:id>9D6749F2-2F93-4D67-910C-2B7D8FDAC2C3</gtr:id><gtr:title>Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for insulin-like growth factor I-mediated regulation of focal adhesion kinase.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/771a782eab14f8ce2ca63859a833bd41"><gtr:id>771a782eab14f8ce2ca63859a833bd41</gtr:id><gtr:otherNames>Kiely PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C474F05C-5377-4EE4-8DC3-C0CD2C8FF0E4"><gtr:id>C474F05C-5377-4EE4-8DC3-C0CD2C8FF0E4</gtr:id><gtr:title>MEK1 binds directly to betaarrestin1, influencing both its phosphorylation by ERK and the timing of its isoprenaline-stimulated internalization.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b0457324b4db06708dfba291ef09e54"><gtr:id>9b0457324b4db06708dfba291ef09e54</gtr:id><gtr:otherNames>Meng D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EAE483B6-79FF-40F3-BE07-A4119A59E7AD"><gtr:id>EAE483B6-79FF-40F3-BE07-A4119A59E7AD</gtr:id><gtr:title>Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/864889f4420c2c7f78b06979774e632d"><gtr:id>864889f4420c2c7f78b06979774e632d</gtr:id><gtr:otherNames>Hayashi-Takagi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B9F558B2-A5BA-4808-9C48-A86B74B2E9A2"><gtr:id>B9F558B2-A5BA-4808-9C48-A86B74B2E9A2</gtr:id><gtr:title>Interaction between LIS1 and PDE4, and its role in cytoplasmic dynein function.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7f1ca97b0dffda2fe87b00adf80d7272"><gtr:id>7f1ca97b0dffda2fe87b00adf80d7272</gtr:id><gtr:otherNames>Murdoch H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FCA63174-9787-48F8-88CD-F239D662B51F"><gtr:id>FCA63174-9787-48F8-88CD-F239D662B51F</gtr:id><gtr:title>Phosphodiesterase-8A binds to and regulates Raf-1 kinase.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1bc22221e02b007ecc36e2cf2f985a7d"><gtr:id>1bc22221e02b007ecc36e2cf2f985a7d</gtr:id><gtr:otherNames>Brown KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0A2FF812-1FEA-42B2-BE42-1BFF6F2E1085"><gtr:id>0A2FF812-1FEA-42B2-BE42-1BFF6F2E1085</gtr:id><gtr:title>A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity.</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b3ee6a846d9c19caa20dd8a1b043a0f8"><gtr:id>b3ee6a846d9c19caa20dd8a1b043a0f8</gtr:id><gtr:otherNames>Serrels B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7E1A9C8C-2D52-4FA8-A1F6-FFC6A16653CF"><gtr:id>7E1A9C8C-2D52-4FA8-A1F6-FFC6A16653CF</gtr:id><gtr:title>Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs: implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKs.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bcc2284555def528ab993e8adea04d60"><gtr:id>bcc2284555def528ab993e8adea04d60</gtr:id><gtr:otherNames>Xu TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1F9550C8-C731-4AB5-8D83-A138EA1B71ED"><gtr:id>1F9550C8-C731-4AB5-8D83-A138EA1B71ED</gtr:id><gtr:title>Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c922c509d07d982116722e1f090ea640"><gtr:id>c922c509d07d982116722e1f090ea640</gtr:id><gtr:otherNames>Mackenzie KF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E6862E45-5A6F-43CF-945E-D66B7A44A348"><gtr:id>E6862E45-5A6F-43CF-945E-D66B7A44A348</gtr:id><gtr:title>PKA phosphorylation of the small heat-shock protein Hsp20 enhances its cardioprotective effects.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a0341c4ef012fdc6d1bef37517bb1fa9"><gtr:id>a0341c4ef012fdc6d1bef37517bb1fa9</gtr:id><gtr:otherNames>Edwards HV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C4FEC985-4149-4C03-93BA-650B2F8A8F3F"><gtr:id>C4FEC985-4149-4C03-93BA-650B2F8A8F3F</gtr:id><gtr:title>Specific interactions between Epac1, ?-arrestin2 and PDE4D5 regulate ?-adrenergic receptor subtype differential effects on cardiac hypertrophic signaling.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/77c3fa2bfb4c3566b426e980bf94c127"><gtr:id>77c3fa2bfb4c3566b426e980bf94c127</gtr:id><gtr:otherNames>Berthouze-Duquesnes M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DFB8D43E-EE86-4142-8C7C-47AEE5532394"><gtr:id>DFB8D43E-EE86-4142-8C7C-47AEE5532394</gtr:id><gtr:title>Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d68d9d60dc03e9488b19d262c79dce20"><gtr:id>d68d9d60dc03e9488b19d262c79dce20</gtr:id><gtr:otherNames>Kelly MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C19BAF90-57ED-4C68-8C7C-8CCFCD633AA7"><gtr:id>C19BAF90-57ED-4C68-8C7C-8CCFCD633AA7</gtr:id><gtr:title>Cyclic AMP controls mTOR through regulation of the dynamic interaction between Rheb and phosphodiesterase 4D.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aec2c0da12d8ed3afb5674132969266d"><gtr:id>aec2c0da12d8ed3afb5674132969266d</gtr:id><gtr:otherNames>Kim HW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5696E6F8-C2E7-4439-8103-2399D5F428C1"><gtr:id>5696E6F8-C2E7-4439-8103-2399D5F428C1</gtr:id><gtr:title>Phosphodiesterase 4 interacts with the 5-HT4(b) receptor to regulate cAMP signaling.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81bcf1d6a94d1ff7f60348d250ac0035"><gtr:id>81bcf1d6a94d1ff7f60348d250ac0035</gtr:id><gtr:otherNames>Weninger S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6010488-5802-4E3E-9C56-1ED55B418958"><gtr:id>C6010488-5802-4E3E-9C56-1ED55B418958</gtr:id><gtr:title>The psychiatric disease risk factors DISC1 and TNIK interact to regulate synapse composition and function.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/85103be6c0a7ff70942dad56b4330959"><gtr:id>85103be6c0a7ff70942dad56b4330959</gtr:id><gtr:otherNames>Wang Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B2C45939-1358-4982-9405-585F5829D23D"><gtr:id>B2C45939-1358-4982-9405-585F5829D23D</gtr:id><gtr:title>In cardiac myocytes, cAMP elevation triggers the down-regulation of transcripts and promoter activity for cyclic AMP phosphodiesterase-4A10 (PDE4A10).</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c640a488ed782ca29167e2dde18f664b"><gtr:id>c640a488ed782ca29167e2dde18f664b</gtr:id><gtr:otherNames>McCahill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E13FEC52-0B30-4162-8889-2E89E31A45FC"><gtr:id>E13FEC52-0B30-4162-8889-2E89E31A45FC</gtr:id><gtr:title>Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown.</gtr:title><gtr:parentPublicationTitle>Trends in biochemical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0e56f4d61095980aaabb017d2aa7616e"><gtr:id>0e56f4d61095980aaabb017d2aa7616e</gtr:id><gtr:otherNames>Houslay MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0968-0004</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/46C38809-19A4-43B0-9157-A250206DEA91"><gtr:id>46C38809-19A4-43B0-9157-A250206DEA91</gtr:id><gtr:title>Sleep deprivation impairs cAMP signalling in the hippocampus.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b1fb8c7157e338e0f75438c8cf56a5c2"><gtr:id>b1fb8c7157e338e0f75438c8cf56a5c2</gtr:id><gtr:otherNames>Vecsey CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5AEB9C0B-7142-4272-B2B8-E37D2B5B5148"><gtr:id>5AEB9C0B-7142-4272-B2B8-E37D2B5B5148</gtr:id><gtr:title>Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4).</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7d46a299510bcbef6c0115bee738cd56"><gtr:id>7d46a299510bcbef6c0115bee738cd56</gtr:id><gtr:otherNames>Day JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ABA8D3DC-7F8C-43C4-ADA2-C3F4A63AD4FA"><gtr:id>ABA8D3DC-7F8C-43C4-ADA2-C3F4A63AD4FA</gtr:id><gtr:title>Cyclic AMP-specific phosphodiesterase, PDE8A1, is activated by protein kinase A-mediated phosphorylation.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1bc22221e02b007ecc36e2cf2f985a7d"><gtr:id>1bc22221e02b007ecc36e2cf2f985a7d</gtr:id><gtr:otherNames>Brown KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8C1B6CCF-3476-4C22-9618-344089CE9A53"><gtr:id>8C1B6CCF-3476-4C22-9618-344089CE9A53</gtr:id><gtr:title>Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ff77004d944403e74275e253bc8112a8"><gtr:id>ff77004d944403e74275e253bc8112a8</gtr:id><gtr:otherNames>Cullen MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0003D608-D22C-43BA-9119-E959A926409B"><gtr:id>0003D608-D22C-43BA-9119-E959A926409B</gtr:id><gtr:title>Tyrosine 302 in RACK1 is essential for insulin-like growth factor-I-mediated competitive binding of PP2A and beta1 integrin and for tumor cell proliferation and migration.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/771a782eab14f8ce2ca63859a833bd41"><gtr:id>771a782eab14f8ce2ca63859a833bd41</gtr:id><gtr:otherNames>Kiely PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/710E81F6-6B8C-4EEE-AE8F-0F3EFC42FBF0"><gtr:id>710E81F6-6B8C-4EEE-AE8F-0F3EFC42FBF0</gtr:id><gtr:title>Arrestin times for developing antipsychotics and beta-blockers.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0e56f4d61095980aaabb017d2aa7616e"><gtr:id>0e56f4d61095980aaabb017d2aa7616e</gtr:id><gtr:otherNames>Houslay MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/69BABBC2-595D-4294-B6AF-FF1CD67A1541"><gtr:id>69BABBC2-595D-4294-B6AF-FF1CD67A1541</gtr:id><gtr:title>Disrupting specific PDZ domain-mediated interactions for therapeutic benefit.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0e56f4d61095980aaabb017d2aa7616e"><gtr:id>0e56f4d61095980aaabb017d2aa7616e</gtr:id><gtr:otherNames>Houslay MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7C55CCB0-F0B5-411B-AC87-92B68619CEA7"><gtr:id>7C55CCB0-F0B5-411B-AC87-92B68619CEA7</gtr:id><gtr:title>The cardiac IKs potassium channel macromolecular complex includes the phosphodiesterase PDE4D3.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0d83784bfeb73bf9dc1a36ece43eef79"><gtr:id>0d83784bfeb73bf9dc1a36ece43eef79</gtr:id><gtr:otherNames>Terrenoire C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600765</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>